Results of the double-blinded and initial open-label phases of the ELECT Study demonstrate the effectiveness of lanreotide in controlling diarrhea and flushing in patients with NETs presenting with carcinoid syndrome.
Development of carcinoid syndrome has a profound effect on cost of care for patients with neuroendocrine tumors (NETs).
Benefits of long-acting, repeatable octreotide and lanreotide in neuroendocrine tumors, formerly known as carcinoid tumors, are similar.
Patients who receieved lanreotide depot had a significantly lower percentage of days when rescue octreotide was used compared with placebo.
Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.
Findings are presented from an open-label NETTER-1 clinical trial evaluating the efficacy and safety of 177Lu-Dotatate in patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue.
